Epirium Bio Gains FDA Alignment for Phase 2b Trial of First-in-Class Sarcopenia Treatment MF-300
Key Insights
Epirium Bio (search) received positive FDA feedback on its Phase 2b trial design for MF-300, an oral 15-PGDH (search) enzyme inhibitor targeting age-related sarcopenia (search), with alignment on patient population, endpoints, and dosing regimen.
The company plans to initiate a 6-month, randomized, double-blind, placebo-controlled Phase 2b study in the second half of 2026 following successful completion of Phase 1 trials in 82 healthy adults.
MF-300 represents the first-in-class oral treatment for sarcopenia (search), addressing a significant unmet medical need in the absence of approved pharmacologic therapies for this condition.
Epirium Bio (search) Inc. has achieved a significant regulatory milestone with positive outcomes from its Type C End-of-Phase 1 meeting with the FDA, securing alignment on key aspects of a Phase 2b clinical trial for MF-300, a first-in-class oral treatment for age-related sarcopenia (search). The San Diego-based clinical-stage biopharmaceutical company announced that it reached concurrence with the FDA on patient population, primary and secondary efficacy endpoints, treatment duration, and dosing regimen.
Regulatory Alignment Supports Advanced Development
The FDA Type C meeting resulted in several critical agreements that will guide MF-300's continued clinical development. The agency concurred with Epirium's proposed patient population and efficacy endpoints for the Phase 2b study, with both parties agreeing that these endpoints will inform Phase 3 endpoint selection. Additionally, the FDA supported the company's plan to submit a Fast Track Designation request, which would provide greater access to FDA interaction during development and enable priority review.
"We are pleased with the positive outcome of our End-of-Phase 1 meeting with the FDA, which provided constructive guidance on our development strategy for MF-300 in sarcopenia (search)," said Alex Casdin, Chief Executive Officer of Epirium. "Epirium and the FDA are in broad agreement on the major aspects of the proposed Phase 2b clinical trial for MF-300, a first-in-class oral treatment for sarcopenia."
Phase 2b Trial Design and Timeline
Based on the FDA feedback, Epirium plans to initiate a 6-month, randomized, double-blind, placebo-controlled, multi-center Phase 2b study in the second half of 2026. The trial is designed to assess the safety and efficacy of MF-300 in patients diagnosed with age-related sarcopenia (search), building on positive Phase 1 results that demonstrated the drug's safety profile and mechanism of action.
Novel Mechanism Addresses Unmet Medical Need
MF-300 is an investigational, first-in-class, orally administered 15-hydroxyprostaglandin dehydrogenase (search) (15-PGDH (search)) enzyme inhibitor. The drug works by inhibiting 15-PGDH to enhance endogenous prostaglandin E2 (PGE2) signaling, a pathway associated with the beneficial adaptive response to exercise. Preclinical studies demonstrated that MF-300 increases muscle force and improves muscle quality in aged mice and other preclinical models of neurogenic atrophy.
Strong Phase 1 Foundation
The regulatory alignment follows successful completion of a Phase 1 study that evaluated MF-300's safety, pharmacokinetics, and pharmacodynamics in 82 healthy adults across single-ascending-dose (75–800 mg) and multiple-ascending-dose (75–200 mg daily × 5 days) cohorts. The study met all predefined success criteria, with no unexpected or dose-limiting safety findings, no serious adverse events, and no early discontinuations.
Key Phase 1 findings included rapid absorption and dose-dependent increases in exposure with a half-life supporting once-daily dosing. Pharmacodynamic analyses demonstrated clear target engagement with increases in urinary PGE2 and decreases in urinary PGE-MUM, consistent with 15-PGDH (search) inhibition. The magnitude of PGE-MUM reduction matched levels previously associated with improved muscle quality in aged mice.
Clinical Significance for Sarcopenia Treatment
The regulatory progress represents a meaningful advancement for sarcopenia (search) treatment, as noted by Dr. Jose Garcia, Professor in the Department of Medicine, Division of Gerontology and Geriatric Medicine at the University of Washington School of Medicine. "In the absence of approved pharmacologic therapies or established regulatory pathways for sarcopenia, alignment with the FDA on a Phase 2b trial design represents an important milestone for the field," Dr. Garcia stated. "As sarcopenia represents a significant and growing unmet medical need, this agreement is a meaningful step toward advancing therapeutic options for patients affected by age-related muscle loss and weakness."
As the first 15-PGDH (search) inhibitor tested in humans, MF-300's development addresses a critical gap in treatment options for age-related muscle loss and weakness, potentially offering the first pharmacologic intervention for this prevalent condition affecting older adults.